Evidence map›Paper›PMID 39152241›Full record

ReviewCardiology and therapy2024

Milvexian: An Oral, Bioavailable Factor XIa Inhibitor.

Shyon Parsa, Sneha S Jain, Olu Akinrimisi, Carolyn S P Lam, Kenneth W Mahaffey

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shyon ParsaDivision of Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, USA.
Sneha S JainDivision of Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, USA.
Olu AkinrimisiDivision of Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, USA.
Carolyn S P LamNational Heart Center, Singapore, Singapore.
Kenneth W MahaffeyDuke-NUS Graduate Medical School, Singapore, Singapore. kenneth.mahaffey@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct oral anticoagulants have a dose-dependent increased bleeding risk which limits use in certain populations. Studies in both animals and humans with inherited variations in factor XI levels provide a theoretical basis for a drug target capable of addressing current unmet needs. Milvexian is an oral factor XIa inhibitor that has the potential to provide robust anticoagulant effect without increased bleeding compared with current standard of care. Several key studies in the preclinical, phase I, and phase II stages have reported promising safety data in venous thromboembolism and stroke prevention without compromising hemostasis. The planned phase III trials will examine the efficacy of milvexian for prevention of thrombotic events in patients with acute stroke, acute coronary syndrome, and atrial fibrillation.

Indexed as

AnticoagulationAXIOMATIC trialsFactor XIHemostasisLIBREXIA trialsMilvexianVenous thromboembolism

Identifiers

PMID39152241
PMCPMC11607199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.